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Abstract
Introduction: We examined the cost-eff ectiveness of the three diff erent D-dimer measurements in the screening of DVT in models with and witho-
ut calculation of pre-test probability (PTP) score. Moreover, we calculated the minimal cost in DVT detection.
Material and methods: In the group of 192 patients with clinically suspected acute DVT, we examined the three diff erent D-dimer measurements 
(Innovance D-dimer, Hemosil D-dimer HS and Vidas D-dimer Exclusion II) in combination with and without PTP assessment.
Results: The diagnostic alternative employing Vidas D-dimer Exclusion II assay without and with PTP calculation gave lower incremental cost-eff ec-
tiveness ratio (ICER) than the alternative employing Hemosil D-dimer HS assay (0.187 Euros vs. 0.998 Euros per one additional DVT positive patient 
selected for CUS in model without PTP assessment and 0.450 vs. 0.753 Euros per one DVT positive patient selected for CUS in model with PTP asse-
ssment). According to sensitivity analysis, the Hemosil D-dimer HS assay was the most cost eff ective alternative when one patient was admitted to 
the vascular ambulance per day. Vidas D-dimer Exclusion II assay was the most cost eff ective alternative when more than one patient were admitted 
to the vascular ambulance per day. Cost minimisation analysis indicated that selection of patients according to PTP score followed by D-dimer anal-
ysis decreases the cost of DVT diagnosis.
Conclusions: ICER analysis enables laboratories to choose optimal laboratory tests according to number of patients admitted to laboratory. Results 
support the feasibility of using PTP scoring and D-dimer measurement before CUS examination in DVT screening.
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Introduction
Deep vein thrombosis (DVT) occurs in the western 
world with a frequency of approximately 1 per 
1000 individuals per year (1). The clinical conditions 
that predispose DVT are: increasing age, cancer, 
prolonged immobilization, stroke, previous DVT, 
congestive heart failure, hormonal treatment, 
pregnancy or puerperium, acute infl ammatory 
bowel disease, atherosclerotic disease, long air 
travel (2,3). However, DVT also occurs without an 
obvious precipitating factor. As DVT is a condition 
with signifi cant morbidity, rapid diagnosis and ef-
fective anticoagulant treatment is required (4,5).
The test of choice for clinically suspected DVT is 
compression ultrasonography (CUS) (6). The sensi-
tivity for proximal DVT has been reported as 97% 
but for calf DVT it could be considerably less (73%) 
(7). Repeated or serial venous ultrasound examina-
tion is indicated for initially negative examination 
result in symptomatic patients, DVT ‘unlikely’ pa-
tients (by Wells score), and patient with negative 
D-dimer test (8). CUS procedure is time consuming 
and expensive. Therefore, considerable eff orts are 
being made to design diagnostic algorithms to im-
prove the diagnosis of DVT-suspected outpatients.
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In recent years, new diagnostic methods involving 
assessment of clinical probability and D-dimer be-
come proven diagnostic strategy of outpatients 
with suspect DVT (8). The inclusion of D-Dimer 
measurements as a fi rst step in diagnostic work-up 
was recommended (9). Recently, a large number of 
rapid D-dimer assays have been developed for ex-
clusion of DVT. They diff er with respect to assay de-
sign, the monoclonal antibodies employed to cap-
ture the antigen from plasma, the type of calibra-
tors used and the cut-off  levels to exclude DVT. In 
addition, published reports suggest that the posi-
tive and negative predictive values of the various 
commercial D-dimer assays are highly variable (10).
Taking into account the clinical symptoms and 
signs of DVT, calculation of the pre-test clinical 
probability score (PTP) for DVT before D-dimer 
measurement and CUS utilisation could be useful 
(8). PTP for DVT can be calculated using modifi ed 
Wells score with nine items: active cancer, paralysis 
or recent immobilization of the lower limbs, re-
cently bedridden or recent major surgery, local-
ized tenderness, leg swelling, calf swelling, edema 
of symptomatic leg, collateral veins, previous VTE 
and alternative diagnosis (8).
At best, D-dimer alone or in combination with PTP 
score may be used to confi dently exclude DVT 
quickly, removing the necessity for time consum-
ing and expensive imaging techniques.
The aims of this study were two-fold: fi rstly to ex-
amine the cost-eff ectiveness of the three diff erent 
D-dimer measurements in the screening of DVT, 
alone or in combination with PTP, before CUS ex-
amination and secondly to compare the total costs 
of D-dimer assays and CUS utilisation (alone and in 
combination with PTP) in the screening of DVT and 
to identify the diagnostic alternative with minimal 
cost for detecting DVT.
Materials and methods
Subjects
We analyzed data of 192 (95 male and 97 female) 
prospectively identifi ed outpatients with clinically 
suspected acute DVT admitted to the vascular am-
bulance at Department of Clinic for Vascular Sur-
gery, Clinical Centre of Serbia, from January to May 
2011. Patients were referred from primary care 
physicians or sent in from other clinics. Patients 
were excluded if clinical symptoms persisted for 
more than 7 days, if they had been hospitalised for 
more than 3 days at the time of inclusion into the 
study or had been treated with therapeutic doses 
of un-fractionated or low-molecular-weight 
heparin for more than a day or with vitamin K an-
tagonists before attempted inclusion. Patients 
were not excluded if DVT had occurred previously 
in the other leg. All included patients were over 18 
years of age.
All patients were evaluated by the vascular ultra-
sound specialist. The data about gender, age and 
data for calculation of the PTP score were collect-
ed. We used scoring system for patient classifi ca-
tion. One point was awarded for each of the fol-
lowing items if present: active cancer, paralysis or 
recent immobilization of the lower limbs, recently 
bedridden or recent major surgery, localized ten-
derness, leg swelling, calf swelling, edema of 
symptomatic leg, collateral veins, previous VTE. 
Two points were awarded for alternative diagnosis 
(8). Patients with a PTP score of less than two (low 
+ moderate PTP) were considered DVT-unlikely, 
while those with a score of two or more (high PTP) 
were considered DVT-likely (11).
DVT diagnosis was determined by venous duplex 
sonography including CUS and colour Doppler vis-
ualisation of the veins within the symptomatic leg. 
Duplex ultrasound examinations were performed 
by vascular ultrasound specialist according to a 
standardised protocol and report form (12) CUS was 
performed within 3 hours of outpatients admission 
to the vascular ambulance. Patients were classifi ed 
as DVT positive if they had DVT confi rmed by CUS 
or as DVT negative if CUS was negative.
All patients gave informed consent prior to their 
enrolment in the study according to the ethic 
guidelines following the Helsinki Declaration. The 
institutional review committee approved our study 
protocol confi rming that we had followed local bi-
omedical research regulations.
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Methods
Peripheral venous blood was drawn into collection 
tubes (Vacutainer, Becton Dickinson, USA) contain-
ing sodium citrate as anticoagulant (0.105 mol/L). 
Blood sampling was performed within 2 hours of 
outpatients admission to the vascular ambulance. 
Plasma was obtained by centrifugation at 2000 x g 
for 10 min and stored in aliquots at -70 °C. D-dimer 
was determined using three diff erent assays. Vidas 
D-dimer Exclusion II (BioMérieux, Marcy L’Etoile, 
France) is quantitative automated ELISA with fl uo-
rescent detection determined on Mini Vidas Im-
munoanalyser (BioMerieux, Marcy l’Etoile, France). 
Hemosil D-dimer HS (Instrumentation Laboratory, 
Milan, Italy) is automated quantitative latex-based 
immuno-agglutination assay determined on Elite 
Pro (Instrumentation Laboratory, Milan, Italy). In-
novance D-dimer (Siemens Healthcare Diagnostics 
Products GmbH, Germany) is particle-enhanced 
immunoturbidimetric assay determined on BCS 
(Dade-Behring Coagulation System). All three D-
dimer tests were performed on all 192 patients.
Statistical analysis
For both decision-analytic models (DAMs) we set 
the cut-off  value at which the negative predictive 
value (NPV) for D-dimer was at least 95%. For the 
fi rst DAM we calculated the cut-off  value for D-
dimer in the total patients group and for the sec-
ond DAM we calculated the PTP-specifi c cut-off  
value in the DVT-unlikely group (13). D-dimer cut-
off  values for the fi rst DAM were 0.65 mg/L fi brino-
gen equivalent units (FEU), 268 ng/mL and 0.60 
mg/L FEU for Vidas D-dimer Exclusion II, Hemosil 
D-dimer HS and Innovance D-dimer, respectively. 
D-dimer cut-off  values for the second DAM were 
0.68 mg/L FEU, 268 ng/mL and 0.65 mg/L FEU for 
Vidas D-dimer Exclusion II, Hemosil D-dimer HS 
and Innovance D-dimer, respectively. The New-
comb-Wilson hybrid confi dence intervals (CI) score 
was calculated for the number needed to screen 
(NNS). This improved, narrower CI, provides ration-
al estimates when sample size is small (14,15).
All calculations were performed using Microsoft 
Excel, EduStat 2.01 (2005, Alpha Omnia, Belgrade, 
Serbia) and MedCalc for Windows version Version 
9.6.3. (Mariakerke, Belgium). The minimal statistical 
signifi cance was set at P < 0.05. For cost-eff ective-
ness analysis TreeAge module Healthcare version 
1.5.2 was used (TreeAge Software INC., William-
stown, USA).
Outcome, ICER, CMA and sensitivity analysis
The perspective of the incremental cost-eff ective-
ness ratio (ICER) analysis is the clinical laboratory 
setting. To estimate eff ectiveness we calculated 
the number needed to screen (NNS) to fi nd one 
true positive patient selected for CUS. The NNS is 
analogous to “number needed to treat” and it was 
calculated as the reciprocal value of the diff erence 
between the prevalence of true positive patients 
(TPP) and prevalence of false negative patients 
(FNP). The corresponding formula is:
NNS = 1 / [ (prevalence of TPP) – 
(prevalence of FNP)] (16).
The meaning of NNS could be interpreted as the 
number of patients that should be sent to CUS to 
fi nd one DVT positive patient. In other words, the 
smaller the NNS the more accurate is the D-dimer 
test for DVT diagnosis. NNS depends on cut-off  
values for a particular D-dimer assay.
For ICER analysis we also calculated the NNS% 
(100/NNS), a value with a clearer clinical under-
standing. The meaning of NNS% could be inter-
preted as the percentage of patients that should 
be sent to CUS to fi nd one from 100 DVT positive 
patients.
For each DAM we performed ICER analysis by rank-
ing the three alternatives by their increasing costs. 
After eliminating alternatives that were more or 
equally costly and less eff ective than a competing 
alternative (ie; ruled out by simple dominance), the 
ICER of each alternative was calculated as the ad-
ditional cost of that alternative divided by its addi-
tional eff ectiveness, compared with the next most 
costly alternative (17).
Another point of interest was the cost from the 
perspective of a third-party payer - Republic Insti-
tute for Health Insurance (RIHI), the leading health 
care provider, responsible for health care of almost 
the entire Serbian population (7.5 million). Out-
come of interest was DVT diagnosis. If outcomes 
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are known to be equal, only costs are analysed and 
the least costly alternative is chosen (17). We calcu-
lated all direct costs required to diagnose DVT per 
patient:
direct cost = direct cost per D-dimer tests 
+ (number of patients selected for CUS 
× direct cost per CUS examination).
In this cost minimisation analysis (CMA), we com-
pared direct costs for all six strategies (three strat-
egies from the fi rst DAM and three strategies from 
the second DAM).
However, we applied the sensitivity analyses. Sen-
sitivity analyses were conducted for factors that 
could possibly restrict the generalisability of the 
study results. This approach systematically varies 
the critical parameters of variables to determine 
whether the overall decision criteria changes (18). 
In our analysis critical variables are costs and eff ec-
tiveness; we varied them within specifi c intervals 
and recalculated results in order to see the magni-
tude of change on the fi nal estimate. Two-way 
sensitivity analysis was performed by simultane-
ously varying the total costs and eff ectiveness 
within the given intervals (19). NNS were varied 
within the 95% CI and cost according to the 
number of daily outpatients to the vascular ambu-
lance. To the vascular ambulance the average 
number of daily outpatients is 3. The base costs 
used were the average costs per patient using the 
service when 3 patients are admitted to vascular 
ambulance per day. However, for sensitivity analy-
ses we used costs for minimal number of outpa-
tients at the vascular ambulance (1 patient) and for 
10 patients. We assumed that range of 1 to 10 pa-
tients for cost calculation included all necessary 
variation in costs for controls and calibrations. 
Results
Costs calculation
The direct cost estimations were based on the 
costs of diagnostic procedures and staff  doctor 
visits. The consumed diagnostic procedures in-
cluded measurements of D-dimer concentration 
by D-dimer assays, consumables required for op-
eration of the automated analyser and disposables 
needed for specimen collection and sample analy-
sis. Furthermore, diagnostic procedures included 
CUS utilisation.
We calculated costs per patient that used the labo-
ratory service. These costs included cost for D-
dimer test reagents, for controls (low and high), 
calibrators and standards, all calculated per pa-
tient. The assumption for this calculation is that av-
erage number of daily admitted patients to the 
vascular ambulance is three (Table 1). We calculat-
ed the costs for laboratory specialists and labora-
tory technicians. The costs of laboratory specialists 
were the same for all D-dimer analyses, since eval-
uation of results takes approximately same amount 
of time. To this we added the costs for the labora-
tory technician’s time for specimen collection, 
specimen centrifugation and D-dimer measure-
ments. Laboratory technician’s costs were diff er-
ent since every D-dimer assays required diff erent 
time for measurement. In addition, we added the 
cost of a doctor visit. The costs of a doctor visit 
were the same since examination of patients takes 
approximately the same amount of time for all 
screening alternatives. For ICER analysis we sum-
marised cost for D-dimer reagents, costs for the 
laboratory technician’s time, cost of laboratory 
specialist and the cost of a doctor visit. The total 
cost for CMA was calculated by adding the costs 
for CUS procedure to previously mentioned costs. 
The cost for vascular ultrasound specialist is in-
cluded in the cost for CUS procedure.
Due to the fact that we set the cut-off  values at 
which the NPV was at least 95% in every diagnos-
tic alternative FNP were 2. If patients have a low D-
dimer value, the D-dimer level should be re-ana-
lysed after seven days (8). Accordingly, all costs for 
patients with low D-dimer value were doubled.
Administrative costs (e.g. electricity) were exclud-
ed from the calculations since these costs are the 
same for all compared strategies. Non-health care 
costs and indirect costs were not included in the 
analysis. All costs are calculated in Euros.
In order to estimate the average cost per patient 
we used market prices and prices of RIHI for 2011 
(20). The former refers to the average prices for 
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Innovance 
D-dimer assay
Hemosil 
D-Dimer HS 
assay
Vidas D-Dimer
assay
Costs when 1 patient was received at the vascular ambulance1 36.80 29.25 14.77
Costs when 3 patients were received at the vascular ambulance1 14.51 17.06 14.77
Cost when 10 patients were received at the vascular ambulance1 13.04 17.06 7.38
Cost for technician time2 2.43 2.78 1.74
Cost for one offi  ce visit3 3.88 3.88 3.88
Cost for laboratory specialist 4.00 4.00 4.00
Cost for CUS utilisation 84.67 84.67 84.67
Total cost per patient without CUS utilisation for ICER4
Costs when 1 patient was received at the vascular ambulance 47.11 39.91 24.39
Costs when 3 patients were received at the vascular ambulance 24.82 27.72 24.39
Costs when 10 patients were received at the vascular ambulance 23.35 27.72 17.00
1Cost per patient for D-dimer test reagents, plus cost for controls (low and high), calibration and standards. 2Salary for 
laboratory technician (needed for specimen collection, specimen centrifugation and assaying D-dimer based on 1 analysis). 
3The cost of a doctor visit. 4Sum of costs per patient for D-dimer analysis, salary for laboratory personnel and salary for 
laboratory specialist and doctor visit used for ICER analysis. All costs are indicated in Euros.
DVT - deep venous thrombosis, CUS - compression ultrasonography, ICER - incremental cost eff ectiveness ratio
TABLE 1. Total cost per patient for diagnostic resources included in DVT diagnosis.
laboratory tests. The latter refers to the estimated 
actual average prices of staff  doctor visits, labora-
tory technicians, laboratory specialist work, dis-
posables needed for specimen collection and CUS 
utilisation (Table 1).
The decision-analytic models
The fi rst DAM involved all the included outpatients 
(the total patient group) and the selection proce-
dure according to D-dimer measurements. Within 
it we estimated the number of patients selected 
for CUS and costs of three strategies: DVT screen-
ing with Innovance D-dimer reagents; DVT screen-
ing with D-dimer Hemosil HS reagents and DVT 
screening with Vidas D-dimer Exclusion II (Figure 
1, Panel a). In the second DAM selection of patients 
was the fi rstly done according to PTP score. 34 out-
patients had high PTP. As the prevalence of DVT 
patients with high PTP is 75-80% (1,5), CUS was 
performed without D-dimer testing only for these 
34 patients (Figure 1, Panel b). The remaining 158 
patients with low and moderate PTP (DVT-unlikely 
group) were selected for CUS according to D-dim-
er measurements and costs were calculated for 
three strategies as in the previous model.
Base case analysis
The NNS value (1.87) was higher in the fi rst DAM 
than NNS value (1.66) in the second DAM when the 
selection was made according to the Innovance D-
dimer assay. In contrast, NNS values selected ac-
cording to Hemosil D-dimer HS assay and Vidas D-
dimer Exclusion II assays were higher in the fi rst 
DAM (Figure 1, Panel a and Panel b).
Diagnostic strategies employing diff erent D-dimer 
assays were compared using ICER analysis. The re-
sults for both DAM are shown in Table 2. For the 
fi rst DAM, no alternatives were clearly dominated 
by any other. The diagnostic alternative employing 
the Vidas D-dimer Exclusion II assay gave a lower 
ICER value (0.187 Euros per one additional DVT 
positive patient from 100 patients selected for 
CUS) than the alternative employing the Hemosil 
D-dimer assay (0.998 Euros per one additional DVT 
positive patient from 100 patients selected for 
CUS). However, in the second DAM, the Innovance 
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FIGURE 1. DAMs for diagnosing of DVT. Panel A) The fi rst DAM involved all the included outpatients and within it NNS and costs 
for three strategies: DVT screening with the Innovance D-dimer assay; DVT screening with the D-dimer Hemosil HS assay and DVT 
screening with the Vidas D-dimer Exclusion II assay; Panel B) The second DAM involved patients with low and moderate PTP selected 
from the total patients group and NNS for three strategies as in the previous model.
Costs for Innovance D-dimer assay in the fi rst DAM were calculated: cost for every branch multiply by all probabilities for that branch 
eg. 49.64 Euros x 0.045 x 0.229 =0.51 Euros. The costs for all four branches were summarized.
The number needed to screen (NNS); deep vein thrombosis (DVT), pre-test probability (PTP) score, the decision-analytic model 
(DAM) 
N = 192
N = 192
N = 158
N = 34
49.64 euro
49.64 euro
24.82 euro
24.82 euro
55.44 euro
55.44 euro
27.72 euro
27.72 euro
48.78 euro
48.78 euro
24.39 euro
24.39 euro
49.64 euro
49.64 euro
24.82 euro
24.82 euro
55.44 euro
55.44 euro
27.72 euro
27.72 euro
48.78 euro
48.78 euro
24.39 euro
24.39 euro
NNS = 1.87 (1.62–2.48)
NNS = 1.66 (1.44–2.12)
NNS = 1.43 (1.29–1.69)
NNS = 1.44 (1.28–1.75)
NNS = 1.63 (1.42–2.05)
NNS = 1.56 (1.39–1.90)
D-Dimer Vidas assay
D-Dimer Vidas assay
Hemosil D-Dimer assay
Hemosil D-Dimer assay
Innovance D-Dimer assay
Innovance D-Dimer assay
p = 0.771
p = 0.045
p = 0.955
p = 0.581
p = 0.419
p = 0.027
p = 0.973
p = 0.729
p = 0.271
p = 0.031
p = 0.969
p = 0.672
p = 0.328
p = 0.229
p = 0.385
p = 0.615
p = 0.333
p = 0.667
p = 0.380
p = 0.620
p = 0.456
p = 0.544
p = 0.392
p = 0.354
> = 268 ng/ml, N = 118
> = 0.65 mg/L FEU, N = 128
< 268 ng/ml, N = 74
< 268 ng/ml, N = 72
>= 268 ng/ml, N = 86
>= 0.68 mg/L FAU, N = 96
<0.65 mg/L FEU, N = 64
<0.68 mg/L FEU, N = 62
<0.65 mg/L FEU, N = 60
>= 0.65 mg/L FEU, N = 98
<0.60 mg/L FEU, N = 44
> = 0.60 mg/L FEU, N = 148
DVT(+), N = 2
DVT(–), N = 42
DVT(+), N = 86
DVT(–), N = 62
DVT(+), N = 2
DVT(–), N = 72
DVT(+), N = 86
DVT(–), N = 32
DVT(+), N = 2
DVT(–), N = 62
DVT(+), N = 86
DVT(–), N = 42
p = 0.033
p = 0.967
p = 0.633
p = 0.367
p = 0.028
p = 0.972
p = 0.721
p = 0.279
p = 0.033
p = 0.967
p = 0.646
p = 0.354
DVT(+), N = 2
DVT(–), N = 85
DVT(+), N = 62
DVT(–), N = 36
DVT(+), N = 2
DVT(–), N = 70
DVT(+), N = 62
DVT(–), N = 26
DVT(+), N = 2
DVT(–), N = 60
DVT(+), N = 62
DVT(–), N = 36
DVT(+), N = 24
DVT(–), N = 10
High PTP score
Low and moderate PTP score
A
B
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D-dimer assay was more expensive and less eff ec-
tive than the D-dimer Vidas Exclusion II assay 
therefore it was ruled out by simple dominance. 
The diagnostic alternative employing the Vidas D-
dimer Exclusion II assay had a lower ICER (0.450 Eu-
ros per one DVT positive patient from 100 patients 
selected for CUS) than the alternative employing 
the Hemosil D-dimer HS assay (0.753 Euros per one 
DVT positive patient). As a consequence the Vidas 
D-dimer Exclusion II assay was marked as the dom-
inant alternative in the second DAM.
CMA results are presented in Table 3. The total av-
erage cost per patient for each diagnostic alterna-
tive, according to the number of patients selected 
for D-dimer testing and CUS utilisation, in DAMs 
with or without PTP scoring is indicated. It is clear 
that the selection of patients according to PTP 
score followed by D-dimer analysis decreases the 
number of patients selected for CUS examination 
as well as the average cost per patient for all three 
D-dimer assays. The diagnostic alternative em-
ploying PTP scoring followed by Hemosil D-dimer 
HS measurement was less costly in comparison to 
other strategies. Savings were up to 14.26 Euros 
per patient.
Sensitivity analysis
To examine the robustness of the results we per-
formed sensitivity analysis by varying the average 
cost per patient using the service when 1 patient 
and 10 patients are admitted at the vascular am-
bulance per day (Table 1). According to the sensi-
tivity analyses, results were sensitive to the change 
in the cost of the Hemosil D-dimer HS assay. The 
Vidas D-dimer Exclusion II assay gave the lowest 
ICER, but the Hemosil D-dimer HS assay was the 
most cost-eff ective alternative at cost values be-
low 36 Euros in the fi rst DAM and below 21 Euros 
in the second DAM, Figure 2a and 2b. This means 
that the Hemosil D-dimer HS assay was the most 
cost-eff ective alternative if the cost of the assay 
was dropped below 21.5 Euros (base case analysis 
27.72 Euros) for both DAMs. Furthermore, if only 
one patient was admitted to the vascular ambu-
lance per day for the fi rst DAM, Hemosil D-dimer 
HS assay was the most cost-eff ective alternative.
Discussion
The purpose of this study was to assess the three 
diff erent D-dimer measurements followed by CUS 
examination against the same three D-Dimer 
measurement and CUS examination in combination 
with PTP assessment. A CMA was applied since the 
data of the alternatives under investigation 
indicated an equal number of patients with DVT 
diagnosis but revealed signifi cant variation in the 
number of patients selected for CUS and D-dimer 
testing and accordingly diff erent economic burden. 
In addition, ICER analysis was applied since all three 
D-dimer measurements had diff erent eff ectiveness. 
Diagnostic strategies Costs NNS% Δ Costs Δ NNS% C/E ICER
First DAM
Innovance D-dimer assay 30.51 53.4 - - 0.57 -
Vidas D-Dimer assay 32.51 64.1 2.00 10.7 0.51 0.187
Hemosil D-Dimer assay 38.40 70.0 5.89 5.9 0.55 0.998
Second DAM
Vidas D-Dimer assay 27.77 61.3 - - 0.45 -
Innovance D-dimer assay 34.25 60.2 6.48 -1.1 0.57 dominated1
Hemosil D-Dimer assay 40.35 69.4 6.10 8.1 0.58 0.753
1dominated – diagnostic alternative had higher costs and less eff ectiveness compared to the other strategies.
ICER - incremental cost-eff ectiveness ratio, DAM - decision-analytic model, NNS - number needed to screen.
TABLE 2. ICER analysis of diagnostic scenarios for the fi rst and the second DAM.
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Costs per one 
analysis 1
N of D-dimer 
analysis
Costs for 
CUS NPS for CUS Total costs
2 Total costs per 
patient3
Innovance D-dimer assay
(the fi rst DAM) 24.82 192 84.67 148 17296.6 90.09
Hemosil D-Dimer assay
(the fi rst DAM) 27.72 192 84.67 118 15313.3 79.76
Vidas D-Dimer assay
(the fi rst DAM) 24.39 192 84.67 128 15520.64 80.84
Innovance D-dimer assay
(the second DAM) 24.82 158 84.67 132 15094.04 78.61
Hemosil D-Dimer assay
(the second DAM) 27.72 158 84.67 120 14540.16 75.73
Vidas D-Dimer assay
(the second DAM) 24.39 158 84.67 130 14860.72 77.39
1Costs when 3 patients received at the vascular ambulance, 2The corresponding formula for total cost is: (N of D-dimer analysis × 
Costs per one D-dimer analyis) + (number of patients selected for CUS × Cost for CUS utilisation), 3Total costs divided by 192.
CMA - cost minimisation analysis, DAM - decision-analytic model, CUS - compression ultrasonography, NPS - number of patients 
selected for CUS.
TABLE 3. CMA of diagnostic scenarios for the fi rst and the second DAM
FIGURE 2. Sensitivity analysis. Panel A) Sensitivity analysis for the fi rst DAM; Panel B) Sensitivity analysis for the second DAM. Sensitiv-
ity analysis shows that the results were sensitive to the change of the Hemosil D-dimer cost. If the cost values for Hemosil D-dimer 
were changed (below 36 Euros in the fi rst DAM and below 21.5 Euros in the second DAM), this assay becomes the most cost-eff ective 
strategy.
cost for Hcmosil D-Dimer assay
CE
 ra
tio
19
.2
9117
21
.5
82
23
.8
73
26
.1
64
28
.4
55
30
.7
46
33
.0
37
35
.3
28
37
.6
19
39
.9
1
0.38358
0.40236
0.42114
0.43992
0.4587
0.47747
0.49625
0.51503
0.53381
0.55259
0.57137
cost for Hcmosil D-Dimer assay
CE
 ra
tio
19
.2
9117
21
.5
82
23
.8
73
26
.1
64
28
.4
55
30
.7
46
33
.0
37
35
.3
28
37
.6
19
39
.9
1
0.42561
0.44069
0.45576
0.47084
0.48592
0.501
0.51607
0.53115
0.54623
0.5613
0.57638
Hemosil DDimer
Innovance DDimer
Vidas DDimer
The scope of the analysis was focused on the 
fi nancial consequences for the third-party payer - 
RIHI (CMA) and the clinical laboratory in hospitals 
(ICER analysis).
From all the diagnostic strategies in both DAMs 
the Vidas D-dimer Exclusion II measurement was 
the most cost eff ective alternative when more 
than one patient were admitted at the vascular 
ambulance per day. However, the Hemosil D-dimer 
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HS assay could signifi cantly reduce clinical labora-
tory costs when one patient was admitted at the 
vascular ambulance per day for the fi rst DAM. The 
advantage of the Vidas D-dimer Exclusion II assay 
over other tests is faster DVT screening. Vidas D-
dimer Exclusion II test, in conjunction with PTP 
scoring, safely excludes DVT in outpatients in 20 
minutes. Use of this test dramatically cut D-dimer 
turnaround times, to 30 minutes from about 2 
hours (21). The use of the Vidas D-dimer Exclusion 
II assay allows a doctor to quickly exclude diagno-
sis of DVT without waiting for costly and time-con-
suming imaging studies.
Contrary to the results of ICER analysis in the CMA 
in our study the best alternative for DVT screening 
was the alternative that employed Hemosil D-dim-
er HS measurements in combination with PTP 
scoring and CUS utilisation. This alternative saved 
1.66 Euros per patient than the alternative which 
employed the Vidas D-dimer Exclusion II measure-
ment. We suppose that additional costs per patient 
could be compensated by faster DVT screening 
and shorter length of stay in vascular ambulance 
when the Vidas D-dimer Exclusion assay was used. 
This could be very important for immediate thera-
peutic intervention which would save future 
healthcare costs.
Our study found signifi cant cost-savings for the 
third-party payer from a reduction in the number 
of imaging tests after applying the second DAM 
for DVT screening. In comparison of two DAMs, 
the most prominent savings were observed with 
Innovance D-dimer (more than 11 Euros per pa-
tient). The savings are not so prominent in case of 
Hemosil D-dimer HS and Vidas D-dimer Exclusion 
II (Table 3) due to the fact that even 34 patient 
hadn’t D-dimer analysis, CUS was performed for 
two more patient which is four times costlier pro-
cedure than D-dimer analysis. Our results on 
savings are in accordance with fi ndings from 
several studies already published in the literature 
(22-25) and indicate the advantage of the second 
DAM against the fi rst as it fulfi ls to a greater degree 
the criteria of clinical eff ectiveness and economic 
effi  ciency. Perone and colleagues (26) used 
decision analytic modelling to compare four 
strategies, incorporating combinations of clinical 
risk scoring, D-dimer and ultrasound, with a ‘no 
treatment’ alternative. They estimated that the 
cheapest alternative (combining clinical risk 
scoring and D-dimer with a single ultrasound) was 
also the most cost-eff ective. This alternative was 
similar to the second DAM in our analysis. However, 
it can be argued that no signifi cant opportunity 
cost was lost as a result of PTP score calculation. 
There is a possibility of minimal costs associated 
with time spent on recording the answers to nine 
questions for the PTP score questionnaire. This ex-
tra time of about 2–5 minutes was too small to sig-
nifi cantly change the costs of the strategies. 
Moreover, the results of other studies confi rmed 
advantage of using PTP score before D-dimer 
mesaurement and CUS utilization in practice. Van 
Belle et al. (27) investigated more than 3000 symp-
tomatic patients and found that the combination 
of a low PTP with low D-dimer eff ectively exclud-
ed pulmonary embolism, with only a 0.5% inci-
dence of DVT in 3-month follow-up. Howeever, 
Sartori et al. evaluated the diagnostic accuracy of 
PTP score and D-dimer assay for isolated distal 
DVT. According to their results, D-dimer had a bet-
ter NPV than PTP, but neither of these analyses had 
suffi  cient diagnostic accuracy for isolated distal 
DVT. However, in patients with low PTP, D-dimer 
had a negative predictive value of > 95% for iso-
lated distal DVT (28).
The study is representative to the vascular ambu-
lance at Department of Clinic for Vascular Surgery, 
Clinical Centre of Serbia. In the absence of national 
or state-wide data on the number of outpatients 
with DVT presenting at an emergency vascular de-
partment, we have estimated annual national sav-
ings on the assumption that the clinic is represent-
ative of public hospitals with a vascular depart-
ment. From a third-party payer perspective, the 
annual cost savings for 1000 patients with suspect-
ed DVT is about 11,480 Euros if the best screening 
alternative was used in comparison to the worst 
alternative. The total number of patients with clini-
cally suspected acute DVT at the vascular ambu-
lance at Department of Clinic for Vascular Surgery, 
Clinical Centre of Serbia is approximately 2500. 
The projected savings for Clinical Centre of Serbia 
are 28,700 Euros. However, Mahan et al. developed 
http://dx.doi.org/10.11613/BM.2013.012 Biochemia Medica 2013;23(1):96–106
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a decision tree and cost model to estimate the 
United States (US) health care costs for total DVT, 
total hospital-acquired DVT, and total “preventa-
ble” DVT. Annual total DVT cost ranges in 2010 
were $7.5 to $39.5 billion (5,6 to 29.9 billion Euros). 
When the sensitivity analysis was applied (taking 
into consideration higher incidence rates and 
costs) annual US total DVT costs ranged from $9.8 
to $52 billion (from 7.42 to 39.36 billion Euros) (29).
Conclusion
Our results support the feasibility of using PTP 
scoring and D-dimer measurement as the fi rst step 
in DVT screening from a clinical laboratory and a 
third party payer perspective. In times of tight eco-
nomic resources, the introduction of PTP scoring 
before D-dimer measurement and CUS utilisation 
would be highly convenient because it is simple to 
perform. Similarly, implementation of the faster D-
dimer test is feasible not only for a clinical labora-
tory but also from a third-party payer perspective. 
Our study illustrated that the use of ICER enables 
laboratories to choose optimal laboratory tests ac-
cording to number of patients admitted to labora-
tory and it could be a part of integrative approach 
to DVT diagnostics. In addition, analytical evalua-
tion could help to understand where and how cost 
can be restrained.
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